Home / Procedures / Body Contouring / Questions

Questions

Body Contouring questions

Answers drawn from published studies, FDA documents and ASPS and AAD pages. Treatment depends on an exam by a licensed medical provider.

Answers

What patients ask

Is nonsurgical fat reduction permanent?

The fat cells destroyed do not return. The remaining fat cells in the area can still enlarge with weight gain. Kybella improvement held in 82.4% of followed responders at 3 years.[1][2]

When will I see results?

Device changes may show at 3 weeks, with the full effect 3 to 6 months after the last session. Laser lipolysis results first show at about 6 weeks and are apparent by 3 months. Kybella results show 6 to 8 weeks after a session.[1][2][3]

How many sessions does it take?

AAD lists usually 2 sessions for cryolipolysis, 4 to 10 for radiofrequency and 2 for chin injections, spaced 6 to 8 weeks apart. Kybella allows up to 6 sessions at least 1 month apart.[1][2]

How much fat does it remove?

Cryolipolysis cut abdominal circumference a mean 3.56 cm and suprailiac fat thickness 5.22 mm at 12 weeks across 30 studies. SculpSure reduced flank fat 13% in its clearance study. Submental cryolipolysis reduced fat 2.0 mm.[1][2][3]

How does it compare with liposuction?

AAD states liposuction delivers more dramatic results and non-invasive results are subtle. ASPS states none of these treatments replaces liposuction.[1][2]

Is it a weight-loss treatment?

No. AAD describes good candidates as people with a small bulge whose weight is in the normal range. Body weight did not change significantly in the Emsculpt MRI study.[1][2]

What is paradoxical adipose hyperplasia?

A firm fat mass that grows in the area treated by cryolipolysis, about 3 to 6 months later. A 2025 meta-analysis put the rate at 0.22%, about 1 in 455 patients. No spontaneous resolution has been described; liposuction is the usual treatment.[1][2][3]

Does Emsculpt build muscle?

One MRI study reported rectus abdominis thickness up 15.4% at 2 months. A 2023 systematic review found a mean 2.2 mm gain and stated early gains likely reflect muscle swelling.[1][2]

Can Kybella be used outside the chin?

Its FDA label states safe and effective use outside the submental region has not been established and is not recommended.[1]

Who should not have cryolipolysis?

ASPS lists cryoglobulinemia, cold urticaria and paroxysmal cold hemoglobinuria, and notes loose skin or poor tone may make a patient unsuitable. People who are pregnant or breastfeeding should not have nonsurgical fat reduction.[1][2]

Sources

Sources

Checked 2026-10-25. Every fact links to its source.

  1. FDA, ZELTIQ Dermal Cooling Device classification order (De Novo DEN090002 / K080521), 2010
  2. FDA 510(k) database, K120023, ZELTIQ CoolSculpting (abdomen), 2012
  3. FDA 510(k) summary, K133212, CoolSculpting System (thigh), 2014
  4. FDA 510(k) summary, K151179, CoolSculpting System (submental area), 2015
  5. FDA 510(k) summary, K160259, CoolSculpting System (bra fat, back fat, banana roll), 2016
  6. FDA 510(k) summary, K150230, Cynosure SculpSure, 2015
  7. FDA 510(k) summary, K122389, Cutera truSculpt, 2012
  8. FDA 510(k) summary, K180709, Cutera truSculpt RF Device (abdominal lipolysis), 2018
  9. FDA 510(k) summary, K201285, InMode Evolve System with the Tone Applicator, 2021
  10. FDA 510(k) summary, K210877, Evolve System with the T3 Applicator, 2021
  11. FDA, KYBELLA (deoxycholic acid) injection prescribing information, 2015
  12. FDA, KYBELLA NDA 206333 approval letter, 2015
  13. ASPS, Nonsurgical fat reduction
  14. ASPS, Nonsurgical fat reduction: cryolipolysis
  15. ASPS, Nonsurgical fat reduction: injection lipolysis
  16. ASPS, Nonsurgical fat reduction: radiofrequency lipolysis
  17. ASPS, Nonsurgical fat reduction: laser lipolysis
  18. AAD, Non-invasive fat removal: what can you expect?
  19. Manstein D et al. Selective cryolysis: a novel method of non-invasive fat removal. Lasers Surg Med 2008
  20. Zelickson B et al. Cryolipolysis for noninvasive fat cell destruction: initial results from a pig model. Dermatol Surg 2009
  21. Nelson AA, Wasserman D, Avram MM. Cryolipolysis for reduction of excess adipose tissue. Semin Cutan Med Surg 2009
  22. Avram MM, Harry RS. Cryolipolysis for subcutaneous fat layer reduction. Lasers Surg Med 2009
  23. Coleman SR et al. Clinical efficacy of noninvasive cryolipolysis and its effects on peripheral nerves. Aesthetic Plast Surg 2009
  24. Kilmer SL, Burns AJ, Zelickson BD. Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat. Lasers Surg Med 2016
  25. Ravindran R et al. Cryolipolysis and associated health outcomes, adverse events, and satisfaction: a systematic review and meta-analysis. Obes Rev 2025
  26. Epstein EH Jr, Oren ME. Popsicle panniculitis. N Engl J Med 1970
  27. Harley OJ, Pickford MA. CT analysis of fat distribution superficial and deep to the Scarpa's fascial layer. J Plast Reconstr Aesthet Surg 2013
  28. Decorato JW et al. Subcutaneous adipose tissue response to a non-invasive hyperthermic treatment using a 1,060 nm laser. Lasers Surg Med 2017
  29. Mah AE et al. Incidence of paradoxical adipose hyperplasia after cryolipolysis: a systematic review and meta-analysis. Aesthet Surg J Open Forum 2025
  30. Jalian HR et al. Paradoxical adipose hyperplasia after cryolipolysis. JAMA Dermatol 2014
  31. Singh SM et al. Paradoxical adipose hyperplasia secondary to cryolipolysis: an underreported entity? Lasers Surg Med 2015
  32. Kelly ME et al. Treatment of paradoxical adipose hyperplasia following cryolipolysis: a single-center experience. Plast Reconstr Surg 2018
  33. Friedmann DP et al. Real-world use and adverse events from 3262 patients treated with 18,203 cycles of cryolipolysis. Aesthet Surg J 2025
  34. Nishikawa A et al. Adverse events associated with cryolipolysis: a prospective observational study with 3-month follow-up. Plast Reconstr Surg 2026
  35. Nguyen CN et al. Adverse events of non-invasive body contouring: analysis of the FDA MAUDE database. Dermatol Surg 2022
  36. Wulkan AJ et al. Complications with noninvasive fat and cellulite reduction devices: a cross-sectional analysis of the FDA MAUDE database. Dermatol Surg 2022
  37. Benoit C, Modarressi A. Severe frostbite complication after cryolipolysis: a case report. JPRAS Open 2020
  38. Fajkosova K et al. Selective radiofrequency therapy as a non-invasive approach for contactless body contouring. J Drugs Dermatol 2014
  39. Hayre N et al. A clinical evaluation of a next generation, non-invasive, selective radiofrequency, hands-free, body-shaping device. J Drugs Dermatol 2016
  40. Fritz K, Salavastru C. Long-term follow-up on patients treated for abdominal fat using a selective contactless radiofrequency device. J Cosmet Dermatol 2017
  41. Taub A, Bartholomeusz J. Ultrasound evaluation of a single treatment with a temperature controlled multi-frequency monopolar radio frequency device. J Drugs Dermatol 2020
  42. Kinney BM, Lozanova P. High intensity focused electromagnetic therapy evaluated by magnetic resonance imaging. Lasers Surg Med 2019
  43. Samuels JB, Katz B, Weiss RA. Radiofrequency heating and high-intensity focused electromagnetic treatment delivered simultaneously: the first sham-controlled randomized trial. Plast Reconstr Surg 2022
  44. Kohan J et al. HIFEM energy with and without radiofrequency for noninvasive body contouring: a systematic review. Aesthetic Plast Surg 2024
  45. Swanson E. A systematic review of electromagnetic treatments for body contouring. Ann Plast Surg 2023
  46. Jones DH et al. REFINE-1, a phase 3 trial with ATX-101 for submental fat reduction. Dermatol Surg 2016
  47. Humphrey S et al. ATX-101 for reduction of submental fat: a phase III randomized controlled trial (REFINE-2). J Am Acad Dermatol 2016
  48. Humphrey S et al. Improvements in submental contour up to 3 years after ATX-101. Aesthet Surg J 2021
  49. Shridharani SM, Kennedy ML. Management of serious adverse events following deoxycholic acid injection. Aesthet Surg J Open Forum 2024
  50. Rotunda AM et al. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation. Dermatol Surg 2004